GeoVax Labs (GOVX) Retained Earnings (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Retained Earnings of -$160.5 million for Q2 2026, down 14.58% year-over-year from -$187.9 million in Q2 2025, and down 6.42% quarter-over-quarter from -$150.8 million in Q4 2025.
GeoVax Labs (GOVX) Retained Earnings (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Retained Earnings for 17 consecutive years, with -$160.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings fell 14.58% year-over-year to -$160.5 million; the TTM figure through Jun 2026 stood at -$160.5 million (down 14.58% YoY), while the FY2025 annual figure was -$150.8 million, down 16.59% from the prior year.
- Retained Earnings eased to -$160.5 million in Q2 2026 per GOVX's latest filing, from -$150.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$66.8 million in Q1 2022 and bottomed at -$160.5 million in Q2 2026.
- Historically, Retained Earnings has averaged -$109.9 million across 5 years, with a median of -$110.2 million in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 44.2% — and 2026, when it dropped 14.58%.
- GeoVax Labs' Retained Earnings stood at -$78.4 million in 2022, then plunged by 33.12% to -$104.4 million in 2023, then declined by 23.95% to -$129.4 million in 2024, then fell by 16.59% to -$150.8 million in 2025, then fell by 6.42% to -$160.5 million in 2026.
- Business Quant data shows GOVX's Retained Earnings at -$160.5 million in Q2 2026, -$150.8 million in Q4 2025, and -$146.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 4.38 Bn |
| 10 | GeoVax Labs | 2.88 Mn | -267,341.61 | - | -160.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -160.51 Mn |
| Dec 31, 2025 | -150.82 Mn |
| Sep 30, 2025 | -146.40 Mn |
| Jun 30, 2025 | -140.08 Mn |
| Mar 31, 2025 | -134.71 Mn |
| Dec 31, 2024 | -129.36 Mn |
| Sep 30, 2024 | -121.09 Mn |
| Jun 30, 2024 | -115.28 Mn |
| Mar 31, 2024 | -110.21 Mn |
| Dec 31, 2023 | -104.36 Mn |
| Sep 30, 2023 | -96.77 Mn |
| Jun 30, 2023 | -88.36 Mn |
| Mar 31, 2023 | -82.43 Mn |
| Dec 31, 2022 | -78.40 Mn |
| Sep 30, 2022 | -73.01 Mn |
| Jun 30, 2022 | -69.05 Mn |
| Mar 31, 2022 | -66.80 Mn |
| Dec 31, 2021 | -64.38 Mn |
| Sep 30, 2021 | -50.63 Mn |
| Jun 30, 2021 | -48.68 Mn |